Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
150 hedge funds and large institutions have $1.21B invested in Esperion Therapeutics in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 45 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
23% more capital invested
Capital invested by funds: $987M → $1.21B (+$224M)
20% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 45
15% more funds holding
Funds holding: 131 → 150 (+19)
0.7% less ownership
Funds ownership: 94.73% → 94.04% (-0.7%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
46% less call options, than puts
Call options by funds: $23M | Put options by funds: $42.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$83.4M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$28.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$16.1M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$12.3M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$33.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$24.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.9M |
| 4 |
PC
Paulson & Co
New York
|
-$9.74M |
| 5 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$8.78M |
ESPR Hedge Fund Activity: Q3 2017 in Review
150 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2017, worth a combined $1.21B — up 23% from $987M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ESPR positions and 13 closed out — a net gain of 20 holders — while 54 added to existing stakes and 45 trimmed.
The largest buyer was Meditor Group, adding an estimated $83.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $33.9M sold.
- 150 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2017, up from 131 in Q2 2017.
- Funds reported $1.21B of Esperion Therapeutics stock for Q3 2017, up 23% quarter-over-quarter.
- 33 funds opened new Esperion Therapeutics positions in Q3 2017 and 13 closed out, a net change of +20 holders.
- The largest Esperion Therapeutics buyer in Q3 2017 was Meditor Group, an estimated $83.4M added.
- The largest Esperion Therapeutics seller in Q3 2017 was RA Capital Management, an estimated $33.9M sold.
Based on aggregated 13F filings for Q3 2017.